uniQure N.V. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your Rights - QURE

The Gross Law Firm has announced legal action against uniQure N.V. (NASDAQ: QURE) for alleged securities law violations that may have impacted investors significantly. Shareholders who purchased stock in uniQure during the class period from September 24, 2025, to October 31, 2025, are particularly encouraged to contact the firm to discuss potential claims and to consider seeking lead plaintiff status. However, it's noted that lead plaintiff status is not mandatory for participation in recovery efforts.

The legal complaint claims that uniQure issued materially false or misleading statements during the class period. Specifically, allegations indicate that the design of uniQure's pivotal study, which involved comparing study results to an external historical data set known as ENROLL-HD, lacked full FDA approval. Additionally, the defendants allegedly downplayed the likelihood of delaying the submission timeline for their Biologics License Application (BLA) in order to conduct further studies, casting doubt on the positive results initially presented from the pivotal study. Consequently, these misrepresentations supposedly led to a distorted view of the company's business outlook.

Investors are advised that the deadline to register for the class action or seek lead plaintiff designation is April 13, 2026. By registering, shareholders will be enrolled in a monitoring service that provides updates throughout the case's progression. The Gross Law Firm emphasizes its commitment to safeguarding investors' rights and seeking redress for those who have experienced losses linked to alleged corporate misconduct.

For more information or to register, investors can visit their website or contact the firm directly. Further announcements and updates regarding the case are expected as it develops.

As a financial analyst, it is essential to stay vigilant about developments that could impact stock performance. Presently, uniQure N.V. (NASDAQ: QURE) is under scrutiny due to a recent lawsuit alleging securities law violations during a specific class period, which ran from September 24, 2025, to October 31, 2025. The complaints highlight concerns about the accuracy of statements made by the company regarding FDA approvals and the timeline for their Biologics License Application (BLA).

Investors should approach this situation with caution. The allegations suggest that uniQure may have failed to adequately disclose critical information that could influence its securities' valuation. If proven, such negligence could lead to a significant reassessment of the stock price, particularly if further delays in the BLA submission arise from the findings of additional studies required by the FDA.

For current shareholders, this might be an opportune moment to consult legal counsel, as the Gross Law Firm is actively seeking lead plaintiffs. Registering before the April 13, 2026 deadline could provide affected shareholders with avenues for potential recovery should the claims result in favorable judgments or settlements.

With the potential for short-term volatility in uniQure's stock price due to legal proceedings, investors might consider evaluating their exposure to QURE. Diversification of the investment portfolio could mitigate risks associated with this lawsuit. For those contemplating new positions, caution is advised until more definitive information about the outcome of the legal proceedings is available.

To summarise, shareholders of uniQure should take proactive measures to inform themselves of their rights in light of the current lawsuit, while more broadly, investors should maintain a careful approach to trading in QURE shares amid these unfolding legal developments.